Merck/Endocyte Mulling Vintafolide’s Future After Failure In Ovarian Cancer
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Endocyte is potentially propelled back to a Phase I company after its nearest commercial prospect flops and its collaboration with Merck is expected to disintegrate now that the drug missed PFS in ovarian cancer.